Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Douglas T. Dieterich, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01654939
First received: July 30, 2012
Last updated: September 25, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: September 2015
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)